Child Kidney Dis.  2022 Dec;26(2):86-90. 10.3339/ckd.22.031.

Two pediatric cases with hematuria, normal renal function and positive antineutrophil cytoplasmic antibodies

• Lim JH
• Jung JW
• Go HJ
• Lee JH
• Park YS

• KMID: 2538739
• DOI: http://doi.org/10.3339/ckd.22.031

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis requires prompt diagnosis and treatment, since renal function at the time of diagnosis is significantly associated with renal outcomes. Here, we report two pediatric patients with ANCA-positive glomerulonephritis initially presenting with hematuria, mild proteinuria, and normal renal function. The first patient with a high myeloperoxidase-ANCA titer (>134 IU/mL) was diagnosed with rapidly progressive glomerulonephritis based on renal biopsy and treated with immunosuppressive therapy after 10 months of follow-up. The second patient with a low myeloperoxidase-ANCA titer (11 IU/mL) maintained normal kidney function without medication. Two cases showed different clinical course according to ANCA titer.

Keyword

Antineutrophil cytoplasmic antibody; Case reports; Glomerulonephritis; Rapidly progressive glomerulonephritis; Vasculitis

Figure

• 

  Fig. 1. Pathological findings. (A) A glomerulus with segmental cellular crescent and thin and delicate glomerular capillary walls (periodic acid-Schiff stain, ×400). (B) Mild interstitial inflammatory cell infiltration and fibrosis (hematoxylin & eosin stain, ×400).

Reference

References

1. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003; 63:1164–77.

2. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002; 62:1732–42.

3. Vergunst CE, van Gurp E, Hagen EC, van Houwelingen HC, Hauer HA, Noel LH, et al. An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis. 2003; 41:532–8.

4. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003; 41:776–84.

5. Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016; 68:1700–10.

6. Cohen RA, Brown RS. Microscopic hematuria. N Engl J Med. 2003; 348:2330–8.

7. Guchelaar NAD, Waling MM, Adhin AA, van Daele PLA, Schreurs MWJ, Rombach SM. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun Rev. 2021; 20:102716.

8. Gaffo AL. Diagnostic approach to ANCA-associated vasculitides. Rheum Dis Clin North Am. 2010; 36:491–506.

9. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998; 53:743–53.

10. Houben E, Bax WA, van Dam B, Slieker WAT, Verhave G, Frerichs FCP, et al. Diagnosing ANCA-associated vasculitis in ANCA positive patients: a retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine (Baltimore). 2016; 95:e5096.

11. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum. 1993; 36:365–71.

12. Baskin E, Bakkaloglu A, Besbas N, Hascelik G, Saatci U, Gok F, et al. Ceruloplasmin levels in antineutrophil cytoplasmic antibody-positive patients. Pediatr Nephrol. 2002; 17:917–9.

13. Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol. 2017; 12:1680–91.

14. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18:2180–8.

15. Smith RM, Jones RB, Jayne DR. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther. 2012; 14:210.